Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1998 2
2000 2
2001 2
2002 1
2003 2
2004 2
2005 2
2006 5
2007 4
2008 6
2009 6
2010 1
2011 5
2012 9
2013 9
2014 7
2015 7
2016 14
2017 13
2018 10
2019 10
2020 9
2021 12
2022 9
2023 19
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators. Cohen EEW, et al. Among authors: mach n. Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30. Lancet. 2019. PMID: 30509740 Clinical Trial.
Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.
Curigliano G, Gelderblom H, Mach N, Doi T, Tai D, Forde PM, Sarantopoulos J, Bedard PL, Lin CC, Hodi FS, Wilgenhof S, Santoro A, Sabatos-Peyton CA, Longmire TA, Xyrafas A, Sun H, Gutzwiller S, Manenti L, Naing A. Curigliano G, et al. Among authors: mach n. Clin Cancer Res. 2021 Jul 1;27(13):3620-3629. doi: 10.1158/1078-0432.CCR-20-4746. Epub 2021 Apr 21. Clin Cancer Res. 2021. PMID: 33883177 Free article. Clinical Trial.
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, Früh M, Joerger M, Lardinois D, Gelpke H, Mauti LA, Britschgi C, Weder W, Peters S, Mark M, Cathomas R, Ochsenbein AF, Janthur WD, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M; Swiss Group for Clinical Cancer Research (SAKK). Rothschild SI, et al. Among authors: mach n. J Clin Oncol. 2021 Sep 10;39(26):2872-2880. doi: 10.1200/JCO.21.00276. Epub 2021 Jul 12. J Clin Oncol. 2021. PMID: 34251873 Free article. Clinical Trial.
The Future of Cancer Immunotherapy.
Mach N. Mach N. Praxis (Bern 1994). 2023;112(3):156-159. doi: 10.1024/1661-8157/a003975. Praxis (Bern 1994). 2023. PMID: 36855886
Endurance exercise and gut microbiota: A review.
Mach N, Fuster-Botella D. Mach N, et al. J Sport Health Sci. 2017 Jun;6(2):179-197. doi: 10.1016/j.jshs.2016.05.001. Epub 2016 May 10. J Sport Health Sci. 2017. PMID: 30356594 Free PMC article. Review.
Cytokine-secreting tumor cell vaccines.
Mach N, Dranoff G. Mach N, et al. Curr Opin Immunol. 2000 Oct;12(5):571-5. doi: 10.1016/s0952-7915(00)00144-8. Curr Opin Immunol. 2000. PMID: 11007361 Review.
[Reply].
Mach N. Mach N. Med Clin (Barc). 2013 Jan 19;140(2):95. doi: 10.1016/j.medcli.2012.07.015. Epub 2012 Oct 12. Med Clin (Barc). 2013. PMID: 23067783 Spanish. No abstract available.
150 results